Cortagen

What Cortagen is, structurally

Cortagen is a tetrapeptide with a free N-terminal amine and a C-terminal proline.

The formula checks out against the sequence. Four nitrogens means four backbone amides with no side chain adding another, ruling out lysine, arginine, histidine, asparagine and glutamine. The nine oxygens split between the backbone, including two for the free C-terminal acid, and the two acidic side chains.

Charge sits well to the negative side: glutamate, aspartate and the C-terminus contribute three carboxylates against a single N-terminal amine. The peptide is polar and freely water soluble, though no quantitative figure is quoted here. There is no cysteine, so no thiol and no disulfide chemistry, and no aromatic residue anywhere.

The proline is the residue that makes this compound behave differently from an otherwise similar sequence. Its side chain loops back onto its own backbone nitrogen, which makes that amide tertiary and removes the N-H entirely. Two consequences follow. The C-terminal end is conformationally stiff, and the bond immediately before a proline is chemically distinctive. Here that bond is an aspartyl-prolyl linkage, which is the single most important stability fact about this molecule.

Reconstitution and handling

Sterile water is the default solvent, and with no metal center present, PBS or an appropriate assay buffer work equally well. Add diluent down the vial wall, swirl rather than vortex, and let the solution clarify.

One caution concerns pH rather than technique: do not reach for an acidic diluent. The reason is the aspartyl-prolyl bond described below, and a peptide this polar does not need acid to dissolve.

Adsorption is worth allowing for at low concentration, and low-protein-binding tubes reduce measured loss. A small anionic peptide has modest affinity for polypropylene.

This is laboratory preparation chemistry, not dosing, administration, or protocol guidance of any kind.

Storage and stability

Store the lyophilized powder at -20 degrees C, sealed, desiccated and protected from light, and let a cold vial warm before opening. Reconstituted, hold at 2 to 8 degrees C, or aliquot and freeze rather than thawing repeatedly.

The weak point is unusually specific and it is identifiable straight from the sequence. Aspartyl-prolyl bonds are the classic acid-labile linkage in peptide chemistry: under mildly acidic conditions the bond between an aspartate and a following proline hydrolyses considerably faster than an ordinary peptide bond, splitting the chain at that point. Ala-Glu-Asp-Pro places exactly that motif at positions three and four, so this tetrapeptide has a built-in cleavage site that most sequences of its size do not.

The same proline closes off the other liability aspartyl residues usually carry. Aspartate rearranges to isoaspartate through a succinimide ring, formed when the backbone nitrogen of the following residue attacks its side chain, and that nitrogen must bear a hydrogen. Proline's is tertiary, inside its ring, and has none, so the attack cannot occur. An aspartyl-prolyl pair is therefore unusually resistant to isoaspartate formation while being unusually vulnerable to acid.

That leaves one clear liability rather than two. With no cysteine, methionine or tryptophan, oxidation plays no part either. Acid and warmth are the concerns, not air.

These are storage conditions for the material, not dosing or administration guidance.

How Cortagen is tested

Reversed-phase HPLC establishes chromatographic purity as area percent, detected in the low UV near 214 nm. There is no aromatic residue in this sequence, so 280 nm detection would see essentially nothing and is not an option.

Area percent is a chromatographic measure rather than peptide content by weight. Solid-phase synthesis yields a salt, typically trifluoroacetate or acetate, and that counter-ion sits outside the molecular weight above, so the vial contents are not all peptide. Residual trifluoroacetate and deletion sequences are the impurity classes to resolve.

One method detail follows directly from the stability profile. Reversed-phase methods for peptides commonly run with trifluoroacetic acid as an ion-pairing agent, which makes the mobile phase acidic. For a sequence carrying an aspartyl-prolyl bond, standing in acidic mobile phase can generate cleavage products during the run rather than before it, so prompt injection matters more than usual. Both fragments separate well by mass and retention.

Mass spectrometry confirms identity and shows the cleavage fragments clearly, since hydrolysis splits the molecule into two much smaller species.

These describe general methodology, not a claim about any particular batch.